Apr. 21 at 7:27 PM
$NUVB $TNXP two of my favorite biotechs to buy and hold had approvals last year about 5 months apart. For those of you who want another example of how to convert gross Symphony (or IQVIA) sales to net sales, if you look at the weekly data for Ibtrozi (Nuvation’s best in class ROS1 inhibitor) you need a 1.6-2.0x range to get from gross sales.
For TNXP’s Tonmya - a much different drug & disease state (sublingual cyclobenzaprine in fibromyalgia), you need a 1.4-1.7x multiplier- I favor 1.7x based on the data so far, and @dachshund36 is at 1.5x - but neither raw sales report tells the whole number.
Just comparing these two companies, it’s clear that NUVB is undervalued by 2-3x - and TNXP, at a market cap a TENTH the size of Nuvation, could realistically 10-30x over the next year.
Key difference: CEO & CFO & IR (David Hung sold Medivation to
$PFE for a nice premium; Seth is still a first time CEO that has relied on dilution in the past).
@Night_Owl_Biotech : what did I miss? ☘️ 🐂 GLB
